21st Century Cures Act is helping drive expansion in the cellular therapies, with the field valued at $25 billion.When the U.S. Food and Drug Administration issued new guidance earlier this month on how companies who handle human cells, tissues and cellular and tissue-based products should report problems to the agency, it was a recognition that the medical industry is heading deeper into uncharted territory.But FDA Commissioner Scott Gottlieb recognized that it was still early-going, calling the policy “another step forward in our development of a comprehensive framework for regulating cell and tissue products one that provides clear rules and balances patient protection with the need for efficient oversight of these technologies.”

Source: Click here

Share this article

Facebook Comments